Press Releases

April 04, 2022
Venatorx Pharmaceuticals announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
March 10, 2022
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.
December 02, 2021
With over 20 years’ experience in infectious disease, oncology, rare and orphan diseases and academia, Dr. McConnell will be responsible for leading the medical affairs function at Venatorx and will oversee the planning and execution of medical strategy, field medical engagement and scientific communications.

In the News

April 04, 2022
One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.
April 04, 2022
AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”
April 04, 2022
A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

Upcoming Events

Thursday, June 09, 2022 - Monday, June 13, 2022
Monday, June 13, 2022 - Thursday, June 16, 2022